| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/22/2004 | US20040014758 Benzylcycloalkyl amines as modulators of chemokine receptor activity |
| 01/22/2004 | US20040014754 Urea substituted imidazoquinolines |
| 01/22/2004 | US20040014751 Antidiabetic agents |
| 01/22/2004 | US20040014747 CRF receptor antagonists and methods relating thereto |
| 01/22/2004 | US20040014708 Composition comprising immunogenic microparticles |
| 01/22/2004 | US20040014705 Supplying polypeptides; coupling with controller; therapy for autoimmune disease |
| 01/22/2004 | US20040014685 Compounds, compositions and methods for treatment of inflammatory diseases and conditions |
| 01/22/2004 | US20040014684 Hepatoprotective activity of 2'-p-hydroxybenzoylmussaenosidic |
| 01/22/2004 | US20040014656 Method for diagnosing neuronal deseases and for treating primary hemostasis deficiency |
| 01/22/2004 | US20040014655 Pharmaceutical compositions containing plasma protein |
| 01/22/2004 | US20040014208 Methods for culturing human lung mast cells and uses thereof |
| 01/22/2004 | US20040014171 Soluble CTLA4 mutant molecules and uses thereof |
| 01/22/2004 | US20040014141 Comprises transcription factor referred to as dragon protein (DRG) for treating and diagnosing nervous system, skin, muscle, bone and eye disorders |
| 01/22/2004 | US20040014136 Crystal structure of complement inhibitor (sCR1) for preventing hemolysis, necrosis and tissue destruction |
| 01/22/2004 | US20040014132 Comprises immunoglobulins which binds and neutralizes chemoattractants (eotaxin) for modulating inflammatory response; antiinflammtory agents; antiallergens |
| 01/22/2004 | US20040014111 Methods for the identification of IKKalpha function and other genes useful for treatment of imflammatory diseases |
| 01/22/2004 | US20040014110 Dendritic enriched secreted lymphocyte activation molecule |
| 01/22/2004 | US20040014046 Preparing candidate vaccine agents based on a polypeptide comprising an envelope protein of a pathogenic strain of the retrovirus and selecting as the vaccine a modified polypeptide that induces an immune response |
| 01/22/2004 | US20040013747 An anaesthetic mixture comprising a drug, acids, a metal nitrite; a membrane is used to prevent direct contact of the skin while diffusing the active drug and nitric oxide vasodilator; topical application |
| 01/22/2004 | US20040013746 Antidepressants for treating manic disorders, psychosis, comprising ethyl cellulose, talc, polyvinylpyrrolidone |
| 01/22/2004 | US20040013727 Hydrophilic gel foaming matrix; cellulose ethers |
| 01/22/2004 | US20040013718 Three-dimensional body; antiinflammatory agents, autoimmune diseases; in situ response; side effect reduction |
| 01/22/2004 | US20040013706 Stress and radiation resistance; antiallergens; antiinflammatory agents |
| 01/22/2004 | US20040013696 Topical applying |
| 01/22/2004 | US20040013681 Stimulant of immunology response |
| 01/22/2004 | US20040013676 Administering dosage of mature dendritic cells in carrier |
| 01/22/2004 | US20040013645 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 01/22/2004 | DE10230381A1 Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen Use of inhibitors of alanyl-aminopeptidase, and pharmaceutical preparations comprising them |
| 01/22/2004 | CA2800113A1 Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| 01/22/2004 | CA2494245A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | CA2493373A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 01/22/2004 | CA2492561A1 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | CA2492433A1 Organic amine salts of poorly soluble probucol esters and ethers |
| 01/22/2004 | CA2492430A1 Phenylalanine enamide derivatives |
| 01/22/2004 | CA2492427A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492421A1 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them |
| 01/22/2004 | CA2492383A1 Transplant acceptance inducing cells of monocytic origin and their preparation and use |
| 01/22/2004 | CA2492381A1 Phenylalanine enamide derivatives containing a spiro[3.5]non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | CA2492330A1 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 01/22/2004 | CA2492251A1 Sulphonylpiperidine derivatives containing an alkenyl or alkynly moiety for use as matrix metalloproteinase inhibitors |
| 01/22/2004 | CA2492164A1 Substituted benzylamine derivatives and methods of use |
| 01/22/2004 | CA2492093A1 Topical treatment of skin diseases |
| 01/22/2004 | CA2492086A1 Sulphonylpiperidine derivatives containing an aryl or heteroaryl group for use as matrix metalloproteinase inhibitors |
| 01/22/2004 | CA2492083A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | CA2492045A1 Substituted amine derivatives and methods of use |
| 01/21/2004 | EP1382603A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF |
| 01/21/2004 | EP1382346A1 Conditioned medium and diffusible biological product produced by incubating entrapped cells |
| 01/21/2004 | EP1382345A2 Uses of inhibitors of hemostasis |
| 01/21/2004 | EP1382339A1 Compositions containing pyrrolo [2,3-d] pyrimidine derivatives |
| 01/21/2004 | EP1382332A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent |
| 01/21/2004 | EP1382330A1 Aqueous-Based pharmaceutical composition |
| 01/21/2004 | EP1381867A2 Method for evaluating the efficacy of treatment with bacterial dna and bacterial cell walls |
| 01/21/2004 | EP1381686A2 Inactivation of genes of the mep pathway |
| 01/21/2004 | EP1381678A2 Nucleic acid modification enzymes |
| 01/21/2004 | EP1381630A2 Vhh single heavy chain antibody and a method for its preparation in a mammal |
| 01/21/2004 | EP1381626A2 Human transporters and ion channels |
| 01/21/2004 | EP1381620A2 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 01/21/2004 | EP1381602A1 Heterocyclyldicarbamides as caspase inhibitors |
| 01/21/2004 | EP1381594A1 Urea compounds useful as anti-inflammatory agents |
| 01/21/2004 | EP1381592A1 1,4-disubstituted benzo-fused compounds |
| 01/21/2004 | EP1381590A1 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| 01/21/2004 | EP1381432A2 Hsa-free formulations of interferon-beta |
| 01/21/2004 | EP1381381A1 Patch for transcutaneous immunization |
| 01/21/2004 | EP1381373A1 A method for treating or preventing a functional vitamin b12 deficiency in an individual and medical compositions for use in said method |
| 01/21/2004 | EP1381372A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 01/21/2004 | EP1381371A2 Hormone replacement therapy |
| 01/21/2004 | EP1381366A2 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 01/21/2004 | EP1381354A2 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders |
| 01/21/2004 | EP1381280A1 Viral vectors and their use in therapeutic methods |
| 01/21/2004 | EP1280799B1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 01/21/2004 | EP1242415B1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 01/21/2004 | EP1128826B1 Chromone enteric release formulation |
| 01/21/2004 | EP1126852B1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 01/21/2004 | EP0999846B1 Phosphatidic acid-based immune modulator composition |
| 01/21/2004 | EP0944397B1 Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
| 01/21/2004 | EP0935463B1 Use of anti-neurogenic inflammatory compounds and compositions |
| 01/21/2004 | EP0727998B1 Oxazoles for treating cytokine mediated diseases |
| 01/21/2004 | CN1469923A Method of extensive culture of antigen-specific cytotoxic T cells |
| 01/21/2004 | CN1469883A Peptide selection method |
| 01/21/2004 | CN1469875A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469874A Pyrazole compounds useful as protein kinase inhibitors |
| 01/21/2004 | CN1469873A Piperidine compounds as anti-allergic |
| 01/21/2004 | CN1469867A Novel phenylalanine derivatives |
| 01/21/2004 | CN1469865A Pyrazole derivatives for the treatment of viral diseases |
| 01/21/2004 | CN1469858A Aspirin-triggered lipid mediators |
| 01/21/2004 | CN1469755A Vaccines containing ribavirin and methods of use thereof |
| 01/21/2004 | CN1469754A Orally administered peptides to ameliorate a therosclerosis |
| 01/21/2004 | CN1469746A A retroviral immunotherapy |
| 01/21/2004 | CN1468601A Picroside-II as one new medicine for preventing and treating allergic and inflammatory diseases |
| 01/21/2004 | CN1135236C 5-membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists |
| 01/21/2004 | CN1135231C 1,2,4-triazolo [4,3B] pyrido [3,2-D] pyridazine derivatives and pharmaceutical compositions containing them |
| 01/20/2004 | US6680372 Antibodies specific for growth differentiation factor-7 |
| 01/20/2004 | US6680337 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| 01/20/2004 | US6680333 Imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 01/20/2004 | US6680318 Piperazinomethylbenzamides as delta-opioid receptor agonists |
| 01/20/2004 | US6680317 N-(phenyl)-n*-(2-hydroxy-3-aminosulfonylphenyl)guanidine derivatives; chemokine inhibitors; respiratory, cardiovascular, rheumatic, brain, and nervous system disorders |
| 01/20/2004 | US6680316 Pyridazin-3-one derivatives and medicines containing the same |
| 01/20/2004 | US6680303 3′,5-difluoro-2′,3′-didehydropyrimidine nucleosides and methods of treatment therewith |
| 01/20/2004 | US6680170 Polynucleotides encoding STE20-related protein kinases and methods of use |
| 01/20/2004 | CA2303498C Dioxocyclopentyl hydroxamic acids |